US30063P1057 - Common Stock

Overall **EXAS** gets a fundamental rating of **3** out of 10. We evaluated **EXAS** against 564 industry peers in the **Biotechnology** industry. Both the profitability and financial health of **EXAS** have multiple concerns. **EXAS** is quite expensive at the moment. It does show a decent growth rate.

In the past 5 years **EXAS** always reported negative net income.

In multiple years **EXAS** reported negative operating cash flow during the last 5 years.

Looking at the **Return On Assets**, with a value of **-2.62%**, **EXAS** belongs to the top of the industry, outperforming **91.27%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -2.62% | ||

ROE | -5.48% | ||

ROIC | N/A |

ROA(3y)-7.36%

ROA(5y)-8.98%

ROE(3y)-14.85%

ROE(5y)-18.14%

ROIC(3y)N/A

ROIC(5y)N/A

In the last couple of years the **Gross Margin** of **EXAS** has remained more or less at the same level.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 73.19% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.07%

GM growth 5Y-0.13%

The number of shares outstanding for **EXAS** has been increased compared to 5 years ago.

Based on the Altman-Z score of **1.38**, we must say that **EXAS** is in the distress zone and has some risk of bankruptcy.

A Debt/Equity ratio of **0.73** indicates that **EXAS** is somewhat dependend on debt financing.

The **Debt to Equity ratio** of **EXAS** (**0.73**) is worse than **76.29%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.73 | ||

Debt/FCF | N/A | ||

Altman-Z | 1.38 |

ROIC/WACCN/A

WACC9.53%

A Current Ratio of **2.17** indicates that **EXAS** has no problem at all paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2.17 | ||

Quick Ratio | 1.98 |

The **Earnings Per Share** has grown by an impressive **26.42%** over the past year.

The **Revenue** has grown by **19.93%** in the past year. This is quite good.

EPS 1Y (TTM)26.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)19.93%

Revenue growth 3Y18.79%

Revenue growth 5Y40.63%

Sales Q2Q%12.78%

The **Earnings Per Share** is expected to grow by **31.77%** on average over the next years. This is a very strong growth

The **Revenue** is expected to grow by **11.71%** on average over the next years. This is quite good.

EPS Next Y0.07%

EPS Next 2Y30.25%

EPS Next 3Y32.62%

EPS Next 5Y31.77%

Revenue Next Year10.59%

Revenue Next 2Y11.11%

Revenue Next 3Y11.17%

Revenue Next 5Y11.71%

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

The **Price/Earnings Ratio** is negative for **EXAS**. In the last year negative earnings were reported.

Also next year **EXAS** is expected to report negative earnings again, which makes the also the **Forward Price/Earnings** Ratio negative.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A |

93.05% of the companies in the same industry are more expensive than **EXAS**, based on the **Enterprise Value to EBITDA** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | 346.12 |

A more expensive valuation may be justified as **EXAS**'s earnings are expected to grow with **32.62%** in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.25%

EPS Next 3Y32.62%

No dividends for **EXAS**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**EXACT SCIENCES CORP**

NASDAQ:EXAS (11/8/2024, 3:07:04 PM)

**51.73**

**-1.5 (-2.82%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap9.56B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -2.62% | ||

ROE | -5.48% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 73.19% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.39

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.73 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2.17 | ||

Quick Ratio | 1.98 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)26.42%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y0.07%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)19.93%

Revenue growth 3Y18.79%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y